InVet 2021, 23 (2): 01-10 ARTÍCULO DE INVESTIGACIÓN ISSN...
It worked with 17 histopathological sections from canine patients with malignant mammary neoplastic. It was evaluated by immunohistochemistry the vascular endothelial growth factor (VEGF), cyclooxygenase-2 (COX-2) expression, estrogen (ER) and progesterone (PR) receptors, Herb2-Neu protooncogene ove...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | Artículo publishedVersion |
| Lenguaje: | Español |
| Publicado: |
Universidad de Buenos Aires. Facultad de Ciencias Veterinarias
2021
|
| Materias: | |
| Acceso en línea: | http://repositoriouba.sisbi.uba.ar/gsdl/cgi-bin/library.cgi?a=d&c=pveterinaria/invet&cl=CL1&d=HWA_6774 https://repositoriouba.sisbi.uba.ar/gsdl/collect/pveterinaria/invet/index/assoc/HWA_6774.dir/6774.PDF |
| Aporte de: |
| Sumario: | It worked with 17 histopathological sections from canine patients with malignant mammary neoplastic. It was evaluated by immunohistochemistry the vascular endothelial growth factor (VEGF), cyclooxygenase-2 (COX-2) expression, estrogen (ER) and progesterone (PR) receptors, Herb2-Neu protooncogene overexpression and p53. The 47 % had positive expression for VEGF, COX-2, Herb2-Neu and p53. This group presented significant differences in relation to the group with negative expression, with a mean survival time of 175 and 850 days respectively. (p=0.009) The 100 % presented negative expression for ER and PR. The 57 % of the simple carcinomas and 100 % of mixed carcinomas presented positive expression for VEGF, COX-2, Herb2-Neu and p53, with lymph node involvement and metastases. The 100 % of the anaplastic carcinomas showed positive expression for VEGF, Herb2-Neu and p53 and negative for COX-2, with lymph node involvement and metastases. Although markers study make it possible to evaluate the risk of metastases, more studies involving a greater number of patients are required to validate or not these findings. The work objective was to investigate the VEGF and COX-2 expression in canine mammary cancer and its association to other marker and metastases risk. |
|---|